Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition

Annals of Oncology

Volumn 25, Issue 5, 2014, Pages 959-967

  Turajlic, S ^a   Furney, S J ^b   Stamp, G ^c   Rana, S ^a   Ricken, G ^a   Oduko, Y ^a   Saturno, G ^b   Springer, C ^a   Hayes, A ^d   Gore, M ^e   Larkin, J ^e   Marais, R ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d The Institute of Cancer Research ^*

^e ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

BRAF; intra tumour heterogeneity; mechanisms of resistance; melanoma; tumour evolution

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; GNAQ PROTEIN, HUMAN; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN PROTEIN, HUMAN;

ADULT; ANTAGONISTS AND INHIBITORS; DRUG RESISTANCE; GENE DELETION; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN GENOME; MALE; MELANOMA; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PERSONALIZED MEDICINE; SECONDARY; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN NEOPLASMS; TREATMENT OUTCOME; TUMOR CELL CULTURE;

ADULT; ANTINEOPLASTIC AGENTS; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; GENOME, HUMAN; GTP-BINDING PROTEIN ALPHA SUBUNITS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INDIVIDUALIZED MEDICINE; MALE; MELANOMA; MUTATION, MISSENSE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS B-RAF; PTEN PHOSPHOHYDROLASE; SEQUENCE DELETION; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 84904729930     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu049     Document Type: Article

References (31)

1. Thirlwell, C., Nathan, P., Melanoma—part 2: management. BMJ, 00, 2008, a2488.
2. Sosman, J.A., Kim, K.B., Schuchter, L., et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366 (2012), 707–714.
3. Hauschild, A., Grob, J.J., Demidov, L.V., et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380 (2012), 358–365.
4. Jang, S., Atkins, M.B., Which drug, and when, for patients with BRAF-mutant melanoma?. Lancet Oncol 14 (2013), e60–e69.
5. Sullivan, R.J., Flaherty, K.T., Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer 49 (2013), 1297–1304.
6. Nazarian, R., Shi, H., Wang, Q., et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468 (2010), 973–977.
7. Romano, E., Pradervand, S., Paillusson, A., et al. Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression. Clin Cancer Res 19:20 (2013), 5749–5757.
8. Wilmott, J.S., Tembe, V., Howle, J.R., et al. Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine. Mol Cancer Ther 11 (2012), 2704–2708.
9. Van Allen, E.M., Wagle, N., Sucker, A., et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov 4 (2014), 94–109.
10. Drmanac, R., Sparks, A.B., Callow, M.J., et al. Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays. Science 327 (2010), 78–81.
11. Van Loo, P., Nordgard, S.H., Lingjaerde, O.C., et al. Allele-specific copy number analysis of tumors. Proc Natl Acad Sci USA 107 (2010), 16910–16915.
12. Venkatraman, E.S., Olshen, A.B., A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics 23 (2007), 657–663.
13. Marais, R., Spooner, R.A., Light, Y., et al. Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination. Cancer Res 56 (1996), 4735–4742.
14. Chapman, P.B., Hauschild, A., Robert, C., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364 (2011), 2507–2516.
15. Berger, M.F., Hodis, E., Heffernan, T.P., et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 485 (2012), 502–506.
16. Pleasance, E.D., Cheetham, R.K., Stephens, P.J., et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463 (2010), 191–196.
17. Pfeifer, G.P., You, Y.H., Besaratinia, A., Mutations induced by ultraviolet light. Mutat Res 571 (2005), 19–31.
18. Van Raamsdonk, C.D., Bezrookove, V., Green, G., et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457 (2009), 599–602.
19. Van Raamsdonk, C.D., Griewank, K.G., Crosby, M.B., et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 363 (2010), 2191–2199.
20. Khalili, J.S., Yu, X., Wang, J., et al. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res 18 (2012), 4345–4355.
21. Yancovitz, M., Litterman, A., Yoon, J., et al. Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma. PLoS One, 7, 2012, e29336.
22. Mitsiades, N., Chew, S.A., He, B., et al. Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy. Invest Ophthalmol Vis Sci 52 (2011), 7248–7255.
23. Paraiso, K.H., Xiang, Y., Rebecca, V.W., et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 71 (2011), 2750–2760.
24. Villanueva, J., Vultur, A., Lee, J.T., et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18 (2010), 683–695.
25. Nathanson, K.L., Martin, A.M., Wubbenhorst, B., et al. Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res 19 (2013), 4868–4878.
26. Trunzer, K., Pavlick, A.C., Schuchter, L., et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol 31 (2013), 1767–1774.
27. Aparicio, S., Caldas, C., The implications of clonal genome evolution for cancer medicine. N Engl J Med 368 (2013), 842–851.
28. Gerlinger, M., Rowan, A.J., Horswell, S., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366 (2012), 883–892.
29. Campbell, P.J., Yachida, S., Mudie, L.J., et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467 (2010), 1109–1113.
30. Burrell, R.A., McClelland, S.E., Endesfelder, D., et al. Replication stress links structural and numerical cancer chromosomal instability. Nature 494 (2013), 492–496.
31. Shi, H., Hugo, W., Kong, X., et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov 4 (2014), 80–93.